Literature DB >> 10225966

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

W G Stetler-Stevenson1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10225966      PMCID： PMC408361          DOI： 10.1172/JCI6870

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  24 in total

Review 1.  ECM and cell surface proteolysis: regulating cellular ecology.

Authors:  Z Werb
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

2.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.

Authors:  G Giannelli; J Falk-Marzillier; O Schiraldi; W G Stetler-Stevenson; V Quaranta
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

3.  Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro.

Authors:  H W Schnaper; D S Grant; W G Stetler-Stevenson; R Fridman; G D'Orazi; A N Murphy; R E Bird; M Hoythya; T R Fuerst; D L French
Journal:  J Cell Physiol       Date:  1993-08       Impact factor: 6.384

4.  Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells.

Authors:  L M Bafetti; T N Young; Y Itoh; M S Stack
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

5.  The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3.

Authors:  H Will; S J Atkinson; G S Butler; B Smith; G Murphy
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

6.  Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

Authors:  P C Brooks; S Strömblad; L C Sanders; T L von Schalscha; R T Aimes; W G Stetler-Stevenson; J P Quigley; D A Cheresh
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

7.  The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.

Authors:  J M Whitelock; A D Murdoch; R V Iozzo; P A Underwood
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

8.  Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2.

Authors:  M W Olson; D C Gervasi; S Mobashery; R Fridman
Journal:  J Biol Chem       Date:  1997-11-21       Impact factor: 5.157

9.  Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9).

Authors:  B C Patterson; Q A Sang
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

10.  Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy.

Authors:  R Benelli; R Adatia; B Ensoli; W G Stetler-Stevenson; L Santi; A Albini
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574
View more
  204 in total

Review 1.  Anticancer drug targets: approaching angiogenesis.

Authors:  E Keshet; S A Ben-Sasson
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Importance of mast cells in the pathophysiology of asthma.

Authors:  Seong H Cho; Andrea J Anderson; Chad K Oh
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

3.  Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells.

Authors:  Giulia Taraboletti; Sandra D'Ascenzo; Patrizia Borsotti; Raffaella Giavazzi; Antonio Pavan; Vincenza Dolo
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

4.  Remodeling in vein expresses arterial phenotype in hyperhomocysteinemia.

Authors:  Poulami Basu; Natia Qipshidze; Suresh C Tyagi; Utpal Sen
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-11-15

5.  Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9).

Authors:  Prasanna K Santhekadur; Rachel Gredler; Dong Chen; Ayesha Siddiq; Xue-Ning Shen; Swadesh K Das; Luni Emdad; Paul B Fisher; Devanand Sarkar
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

Review 6.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

Review 7.  Interferons as antiangiogenic agents.

Authors:  Daniel J Lindner
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

8.  In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.

Authors:  Gabri van der Pluijm; Martine Deckers; Bianca Sijmons; Henny de Groot; John Bird; Ruth Wills; Socrates Papapoulos; Andy Baxter; Clemens Löwik
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

Review 9.  Mathematical modeling of tumor-induced angiogenesis.

Authors:  Nikos V Mantzaris; Steve Webb; Hans G Othmer
Journal:  J Math Biol       Date:  2004-02-06       Impact factor: 2.259

10.  The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells.

Authors:  Ase Bratland; Erlend Ragnhildstveit; Kristin Bjørnland; Kristin Andersen; Gunhild Mari Maelandsmo; Oystein Fodstad; Fahri Saatcioglu; Anne Hansen Ree
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.